Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. In addition, we have taken measures to support the health and well-being of our people. We continue to closely monitor the outbreak to minimize business impact. (CSL is the parent company of CSL Behring and Seqirus)
We have joined with other leading plasma companies to form the CoVIg-19 Plasma Alliance, an unprecedented industry collaboration with a goal of developing and delivering an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19. A Phase III trial is under way.
Also, CSL and AstraZeneca have agreed for CSL to manufacture approximately 50 million doses of the Oxford University vaccine candidate AZD1222, for supply to Australia.
These are just some of our many efforts to combat the global pandemic. To see what else we are doing,, please see our Fact Sheet on CSLBehring.com.
We have taken numerous steps to help ensure the health and safety of our workforce. This includes restricting international travel until 1 July 2021, postponing large group meetings, and encouraging employees to leverage various communication technologies to minimize business disruption.
Our Patients & Products:
CSL continues to provide an uninterrupted supply of our medicines around the world. As the COVID-19 situation evolves, we are closely tracking any impact it could have on our operations.
We have ongoing clinical trials at investigational sites worldwide and remain in close contact with researchers who are involved in this important work to evaluate promising new medicines, discussing the best ways to manage patient visits and follow-up appointments.
Our plasma collection network is operational. Our plasma centers are committed to the highest standards of quality and safety for our employees and donors.